Collectively, ZHX2 protects hepatocytes from abnormal lipid deposition in NAFLD through transcriptional repression of LPL, which subsequently retards cell growth and NAFLD–HCC progression. Here, ZHX2 is linked to metabolic dysfunction-associated steatotic liver disease.